Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - January 2012

 

 

Expertise in Neuropharmacology

  www.neuroact.com

 

    

 

   

Winter News

 

Best Wishes for 2012!

NeuroAct Communication is pleased to complete another successful year of neuropharmacology consulting
and wishes you much happiness
in 2012 !

 

French Psychiatry meeting

Adrian will be presenting at the forthcoming 10th Encéphale Congress on 19th January 2012 in Paris, France. The symposium will be sponsored by AstraZeneca and will focus on the mechanism of action of antipsychotics. More information here.

If you wish to know more about Adrian's neuropharmacology lectures, Contact.

 

Consulting assignments update

NeuroAct Communication is currently giving expert advice on drug discovery flow-charts to a CNS-oriented biomedical firm and providing mechanistic input on psychotropic agents to psychiatrists from a pharmaceutical company.

For more information: Consulting services.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Neurolixis update

Neurolixis Inc. is currently aquiring financing from investors and grant-awarding institutions to support its drug discovery and early development projects on central nervous system disorders, including depression, schizophrenia and Parkinson's disease.


Note: Neurolixis is a CNS-focused biomedical start-up co-founded by Adrian and other experienced neuroscience researchers. Adrian is progressively transitioning to take up research management responsibilities at Neurolixis.

 

 

NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.  

 

NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi Ph.D., an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile

 

 

 

Scientific Communication

Just Published:

S32212: a novel 5-HT2C receptor inverse agonist / alpha2 adrenoceptor antagonist and potential antidepressant. 1. A mechanistic characterization.

Millan MJ, Mannoury LA Cour C, Chanrion B, Dupuis DS, DI Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.
J Pharmacol Exp Ther. 2011 Dec 16. [Epub]

 

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and post-synaptic 5-HT1A receptors in the rat.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Psychopharmacology (Berl). 2011 Dec 3. [Epub].

To find out more about Adrian's scientific communication, see his Publications